MIAKER Developments achieves relevant progress in the preclinical development of innovative compounds to design and test new effective therapies for ALS and other neurodegenerative diseases (ELACOMB) thanks in large part to the funding granted by the Basque Government and the Basque Business Development Agency (SPRI Group), through HAZITEK Business R&D support program.

This funding not only reinforces the R&D&i driven by MIAKER Developments, but also the company's project as a whole.